A prospective study comparing the pharmacokinetics, efficacy, and side effects of sunitinib in patients with advanced renal cell carcinoma
Not Applicable
- Conditions
- Renal cell carcinoma
- Registration Number
- JPRN-UMIN000014685
- Lead Sponsor
- Department of Urology, Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with serious illness in kidney, liver, heart, or hematogenous function 2. Disqualified by a medical doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relationship between trough concentrations of sunitinib and side effects
- Secondary Outcome Measures
Name Time Method Relationship between trough concentrations of sunitinib and efficacy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sunitinib's efficacy in advanced renal cell carcinoma?
How does sunitinib compare to other tyrosine kinase inhibitors in treating advanced renal cell carcinoma?
What biomarkers predict response to sunitinib in patients with advanced renal cell carcinoma?
What are the most common adverse events associated with sunitinib in renal cell carcinoma patients?
Are there combination therapies with sunitinib showing improved outcomes in advanced renal cell carcinoma?